tbuckley/cabot-search huggingface dataset:
THU0054 Glycated Albumin Increases with Disease Activity in Rheumatoid Factor Positive Rheumatoid Arthritis Patients with Normal Fasting Glucose and HBA1C
Authors: J.-S. Park, C.-H. Lee, J.J. Song, Y.-B. Park, S.-K. Lee, S.-W. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a prototypical autoimmune disease, characterized by the symmetric inflammation in multiple joints, leading to progressive destruction of joints. Glycated albumin (GA) is a newly suggested parameter for the glycemic status. GA was reported to be correlated with inflammatory burdens such as (C-reactive protein) CRP and inflammatory cytokines levels [1,2]. <h3>Methods</h3> We consecutively screened 250 RA patients in this study, and finally analyzed data of 205 RA patients. We collected 12 hourfasting blood samples and performed laboratory tests. In this study, we used disease activity score (DAS) 28 using both erythrocyte sedimentation rate (ESR) (DAS28-ESR) and CRP (DAS28-CRP), and we defined DAS28 &gt;3.2 as active RA. <h3>Results</h3> Patients with active RA showed significantly higher GA level than those with inactive RA (13.8 ± 1.8 vs. 12.8 ± 1.4%, P&lt;0.001 (DAS28-ESR) and 14.4 ± 1.7 vs. 13.0 ± 1.5%, P&lt;0.001 (DAS28-CRP)). Patients with active RA had significantly higher alkaline phosphatase (ALP) level than those with inactive RA (P=0.003 (DAS28-ESR) and P=0.033 (DAS28-CRP)). On multivariate logistic regression analysis, GA ≥12.95%, CRP ≥1.65 mg/L and ALP ≥60.5 IU/L were independent predictors of active RA based on DAS28-ESR (OR 4.881, P&lt;0.001, OR 12.972, P&lt;0.001, and OR 3.573, P=0.001). Also GA ≥13.95% could independently predict active RA based on DAS28-CRP better than ESR ≥43.5 mm/hr (OR 6.399, P&lt;0.001 vs. OR 4.509, P&lt;0.001), but ALP ≥60.5 IU/L could not. <h3>Conclusions</h3> GA level increased with disease activity in rheumatoid factor positive RA patients with normal laboratory results, who had no medical history. GA level showed the potential to predict active RA, comparable with ESR and CRP. <h3>References</h3> Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, et al.Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006;5:27. Lu L, Pu LJ, Xu XW, Zhang Q, Zhang RY, Zhang JS, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007;40:810–6. <h3>Disclosure of Interest</h3> None declared
Osteocytes Embedded Inside Bone Are Essential for G-CSF-Induced Hematopoietic Stem/Progenitor Mobilization
Authors: Noboru Asada, Yoshio Katayama, Mari Sato, Kentaro Minagawa, Kanako Wakahashi, Hiroki Kawano, Yuko Kawano, Akiko Sada, Kyoji Ikeda, Toshimitsu Matsui, Mitsune Tanimoto
Journal: Blood (2011)
Mixed Chimerism in T Cells after Allogeneic SCT Allows Early Diagnosis of Graft Rejection and Successful Treatment with Immunosuppression Withdrawal and/or Donor Leukocyte Infusion.
Authors: Ismael Buño, Pascual Balsalobre, Ainhoa Simón, Cintia Manzano, Diana Barroso, David Serrano, Rafael Carrión, Alfonso Gómez-Pineda, José L. Díez-Martín
Journal: Blood (2005)
Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
Authors: Kevin A Carter, Dandan Luo, Aida Razi, Jumin Geng, Shuai Shao, Joaquin Ortega, Jonathan F Lovell
Journal: Theranostics (2016)

Porphyrin-phospholipid (PoP) liposomes can entrap anti-cancer agents and release them in response to near infrared (NIR) light.Doxorubicin, when remotely loaded via an ammonium sulfate gradient at a high drug-to-lipid ratio, formed elongated crystals that altered liposome morphology and could not be loaded into liposomes with higher PoP content.On the other hand, irinotecan could also be remotely loaded but did not form large crystals and did not induce liposome elongation.The loading, stability, and NIR light-triggered release of irinotecan in PoP liposomes was altered by the types of lipids used and the presence of PEGylation.Sphingomyelin, which has been explored previously for liposomal irinotecan, was found to produce liposomes with relatively improved serum stability and rapid NIR light-triggered drug release.PoP liposomes composed from sphingomyelin, cholesterol and 2 molar percent PoP rapidly released irinotecan in vivo in response to NIR irradiation as monitored by intravital microscopy and also induced effective tumor eradication in mice bearing MIA Paca-2 subcutaneous tumor xenografts.
Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study
Authors: Jessica Justman, Jason B Reed, George Bicego, Deborah Donnell, Keala Li, Naomi Bock, Alison Koler, Neena M Philip, Charmaine K Mlambo, Bharat S Parekh, Yen T Duong, Dennis L Ellenberger, Wafaa M El-Sadr, Rejoice Nkambule
Journal: The Lancet HIV (2016)
THU0513 Detection of Subclinical Tophi in Patients with Gouty Arthritis: A Dual-Energy Computed Tomography Study
Authors: I.J. Kim, J.Y. Hwang, J. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tophi are generally considered as manifestations of chronic gout, but subclinical tophi in intra- and extra-articular structures have been shown to occur in early gout and asymptomatic hyperuricemia. Since occurrence of tophi is linked to joint destruction, it is important to detect tophi early before clinical detection. <h3>Objectives</h3> The aim of our study was to evaluate the utility of dual-energy CT (DECT) in detecting subclinical tophi in patients with gouty arthritis. <h3>Methods</h3> DECT scans of feet in 65 patients with gout without apparent clinical tophi were evaluated for presence of tophi. Plain X-ray of feet, clinical and laboratory data were obtained simultaneously at the time of the DECT evaluation. Total volumes of tophi in both feet were quantified using an automated software program of DECT. <h3>Results</h3> Subclinical tophi were detected in 63 (96.9%) patients and in 341 (18.7%) joints, and median 3 (1 to 22) joints per patient were positive for tophi. The most common sites for tophi were first metatarsophalangeal joints (17.6%), followed by ankle joints (10.9%). Tophi in Achilles tendons were present in 10.8% of patients. Patients with early gout (disease duration &lt;2 years) had tophi in 99 (13.6%) joints. Mean number of tophi was significantly lower in patients with early gout compared to those with chronic gout (3.8 versus 6.2, p=0.038). Mean volume of tophi was not significantly different between early gout and chronic gout. <h3>Conclusions</h3> Tophi frequently occur in both intra- and extra-articular structures of gouty arthritis patients despite absence of clinically apparent tophi. DECT is an excellent imaging modality for detecting subclinical tophi. <h3>Disclosure of Interest</h3> None declared
The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Myeloid Cells and Prevents T-Cell-Mediated Hepatic Injury in Mice.
Authors: Anna M. Wolf, Dominik G.F. Wolf, Holger F. Rumpold, Barabara Enrich, Guenther A. Gastl, Gunsilius Eberhard, Herbert Tilg
Journal: Blood (2004)
PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells
Authors: Hiromichi Yuki, Shikiko Ueno, Hiroaki Niiro, Hiro Tatetsu, Hiroyuki Hata, Toshiki Watanabe, Seiji Okada, Koichi Akashi, Hiroaki Mitsuya, Yutaka Okuno
Journal: Blood (2011)
The Addition of Interleukin (IL)-15 to ANTI-CD3, IL-2 and FLT-3 Results in Significant Increase in Expansion, Activation, Proliferation and Survival of Cord Blood (CB) NK Cells and Cytotoxic T-Lymphocyte (CTL) Subsets: Potential for Adoptive Cellular Immunotherapy (ACI).
Authors: Prakash Satwani, Allison F. O’Neill, Janet Ayello, Lynn Simpson, Dustin Cairo, Carmella van de Ven, Mitchell S. Cairo
Journal: Blood (2004)
Abstract 17114: The European Registry of Cardiac Arrest - Study One (EuReCa ONE) - Relationship Between Rates of CPR and Rates of Death in European Countries
Authors: Jan-Thorsten Gräsner, Jan Wnent, Siobhán Masterson, Rudolph W Koster, Ingvild B Myrhaugen Tjelmeland, Bernd W Böttiger, Fernando Rosell Ortiz, Holger Maurer, Johan Herlitz, Leo Bossaert
Journal: Circulation (2015)

Background and Objectives: EuReCa collects data on out-of-hospital cardiac arrest (OHCA) in Europe. In this study (EuReCa ONE) we hypothesised that a higher rate of death is associated with a higher rate of CPR started. We investigated the relationship between the rate of CPR started and total death rates, and also between the rate of CPR started and death rates from ischaemic heart disease (IHD). Methods: We conducted a prospective observational study of EMS attended OHCA from 1 st - 31 st October 2014, covering 201 million inhabitants from 27 European countries. The incidence of cases where CPR was started was calculated per 100,000/year for each country. Data on deaths from IHD and all deaths was obtained from health statistics of the European Commission (Eurostat). Correlations between both these death rates and CPR started rates were calculated. Results: We found a wide range of rates of CPR started (19 - 104/100,000/year) and differences in all death rates (623 - 1417/100,000/year) and IHD death rates (202 - 766/100,000/year). The figures show the relationships for each country. Correlations between the rates of CPR started and rates of death from IHD and total deaths were Pearson R 2 =0.06 (p=0.25); Pearson R 2 = 0.10 (p=0.12) respectively. Conclusion: Correlation is low between the rate of CPR and both the rate of death from all causes and IHD. Differences in mortality rates do not explain the observed variability in the rates of CPR started.
US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry
Authors: Hamid A B Al-Mondhiry, Alice D. Ma, Craig M. Kessler, Margaret Fisher, Robert Z. Gut, David L. Cooper
Journal: Blood (2012)
Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System
Authors: Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Efstathios Kastritis, Dimitrios Christoulas, Magdalini Migkou, Meletios Athanasios Dimopoulos, Christos Papadimitriou
Journal: Blood (2011)
Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT
Authors: Regis Peffault de Latour, Myriam Labopin, Jan Cornelissen, Lars Vindelov, Didier Blaise, Noel Milpied, Anne Huyn, Charles F. Craddock, Nigel Russel, Vladimir Koza, Bruno Lioure, Richard Schouten, Dolores Caballero, Jean-Yves Cahn, Nathalie Fegueux, Mohamad Mohty
Journal: Blood (2012)
Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model.
Authors: Paolo Lunghi, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Attilio Corradi, Anna Maria Cantoni, Nicola Giuliani, Luigi Salvatore, Roberta Riccioni, Antonio Costanzo, Ugo Testa, Massimo Levrero, Vittorio Rizzoli, Antonio Bonati
Journal: Blood (2008)
Is It Time for Synthetic Biodiversity Conservation?
Authors: Antoinette J. Piaggio, Gernot Segelbacher, Philip J. Seddon, Luke Alphey, Elizabeth L. Bennett, Robert H. Carlson, Robert M. Friedman, Dona Kanavy, Ryan Phelan, Kent H. Redford, Marina Rosales, Lydia Slobodian, Keith Wheeler
Journal: Trends in Ecology & Evolution (2016)
Measurement of Functional Cytomegalovirus (CMV)-Specific T Cells by Interferon-gamma-Enzyme-Linked Immunospot (IFN-g ELISPOT) Assay Specific for a Single Immunodominant Epitope Enables the Sensitive Evaluation of Immune Recovery for CMV in Patients after Allogeneic Stem Cell Transplantation (HSCT) with a Reduced-Intensity Regimen (RIST).
Authors: Mutsuko Onishi, Toshiharu Sakurai, Yuji Heike, Yoshinobu Kanda, Yoichi Takaue, Hideaki Mizoguchi, Yutaka Kawakami
Journal: Blood (2004)
CD31 Expression and Gene Polymorphisms in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Authors: Tryfonia Mainou-Fowler, Jean Norden, Alistair Porteous, Sian Davies, Peter Middleton, Annette Nicolle, Stephen Proctor, Anne Dickinson, Geoffrey Summerfield
Journal: Blood (2006)
Formin-Like Gene Expression in Chronic Lymphocytic Leukemia Is Associated with Unfavorable Prognostic Factors and Clinical Outcome
Authors: Eva Calpe, Antonio Martinez, Patricia Favaro, Marta Crespo, Carles Codony, Ma.ÂJoao Gomes Baptista, Eva Gine, Emili Montserrat, Francesc Bosch
Journal: Blood (2008)
In Reply
Authors: George R. Simon, Claire F. Verschragen, Pasi A. Janne, Corey J. Langer, Afsin Dowlati, Shirish M. Gadgeel, Karen Kelly, Gregory P. Kalemkerian, Anne M. Traynor, Guangbin Peng, John Gill, Coleman K. Obasaju, Hedy L. Kindler
Journal: Journal of Clinical Oncology (2008)
Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint
Authors: Athena T Samaras, Sara E Barnato, Benjamin Kim, Stephen Y Lai, A. Oliver Sartor, June McKoy, Brian C Sauer, Charles L. Bennett
Journal: Blood (2008)
Renal Status and Hematuria in Older Patients with Hemophilia
Authors: Pal André Holme, Robert Campbell Tait, Christophe Combescure, Erik Berntorp, Annarita Tagliaferri, Peter Staritz, Roger E.G. Schutgens, Robert Klamroth, Natascha Marquardt, Stephan Rauchensteiner, Philippe De Moerloose
Journal: Blood (2015)
A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.
Authors: Francis J. Giles, Thomas Fischer, Jorge Cortes, James Beck, Farhad Ravandi-Kashani, Guillermo Garcia-Manero, Hagop M. Kantarjian, Bin Peng, Patricia E. Rae, Glen Laird, Samil Sharma, Margaret Dugan, Maher Albitar, Kapil M. Bhalla
Journal: Blood (2004)
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Authors: Ilan Ben‐Zvi, Olga Kukuy, Eitan Giat, Elon Pras, Olga Feld, Shaye Kivity, Oleg Perski, Gil Bornstein, Chagai Grossman, Gil Harari, Merav Lidar, Avi Livneh
Journal: Arthritis & Rheumatology (2016)

Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1–blocking agent, prevented FMF attacks in those with colchicine‐resistant FMF. This study was undertaken to evaluate the efficacy and safety of anakinra in the treatment of colchicine‐resistant FMF, using a randomized controlled trial. Methods Patients with colchicine‐resistant FMF receiving colchicine (dosage ≥1.5 to ≤3 mg/day) were recruited and randomly assigned to receive anakinra or placebo (vehicle). The treatment duration was 4 months. Primary efficacy outcomes were the number of attacks per month, and the number of patients with a mean of &lt;1 attack per month. Quality of life was assessed using a 0–10‐grade visual analog scale (VAS), and safety was assessed according to the number and severity of adverse events. Results Twenty‐five patients with colchicine‐resistant FMF (14 women) were enrolled, of whom 12 were randomized to receive anakinra and 13 to receive placebo. The mean ± SD number of attacks per patient per month was 1.7 ± 1.7 in those receiving anakinra and 3.5 ± 1.9 in those receiving placebo ( P = 0.037). Six patients in the anakinra group, compared to none in the placebo group, had &lt;1 attack per month ( P = 0.005). A beneficial effect of anakinra was noted in the number of attacks in the joints per month in patients receiving anakinra (mean ± SD 0.8 ± 1.6 versus 2.1 ± 1.1 in the placebo group; P = 0.019) and in quality of life (mean ± SD VAS score 7.7 ± 2.3 in the anakinra group versus 4.2 ± 2.9 in the placebo group; P = 0.045). The number of adverse events per patient per month was comparable between the anakinra group and the placebo group (mean ± SD 2.03 ± 1.75 versus 3.34 ± 2.5; P = 0.22). There were no severe adverse events. Conclusion In this randomized controlled trial, anakinra appears to be an effective and safe treatment for colchicine‐resistant FMF.
SAT0342 Features of Orbital Inflammatory Disease and Response To Immunosuppressive Therapy
Authors: A. Casian, S. Sangle (joint first author), R. Malaiya, P. Lutalo, L. Nel, B. Menon, H. Verma, M. Stanford, D. D'Cruz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To characterize a single centre retrospective case series of patients with infra-orbital inflammatory masses with autoimmune disease including granulomatosis with polyangiitis (GPA) (formerly Wegener9s granulomatosis), eGPA (eosinophillic granulomatosis with polyangiitis) or Immunoglobulin G4 (IgG4) related disease (IgG4-RD). <h3>Methods</h3> We identified 30 patients with infra-orbital inflammation on MRI imaging. Clinical and laboratory data was collected from electronic clinical records. Comprehensive Diagnostic Criteria were used for IgG4-RD and Chapel Hill criteria for GPA and eGPA. Statistical analysis was performed by GraphPad software; continuous variables were compared between IgG4-RD and GPA groups using non-parametric Mann-Whitney test and categorical variables were compared by Fisher9s exact test. <h3>Results</h3> The study included 21 Caucasian, 6 Asian and 3 patients of African descent. There were 19 female and 11 male patients. The median age of the patients was 44 years (range 29–76). 13 patients were diagnosed with GPA, 1 with eosinophillic granulomatosis with polyangitis 9eGPA), 11 patients had IgG-RD, 1 patient with lymphoma, 2 other vasculitis, 1 IgA dacryoadenitis, 1 non-specific granuloma. 7/12 patients with IgG4-RD had isolated infra-orbital masses whereas all 14 GPA patients suffered extra-ocular manifestations (p=0.01), usually sino-nasal or pulmonary. 11/14 GPA patients had positive ANCA vs 2/12 patients with Ig4-RD (p=0.04). IgG4 level was elevated pre-treatment in IgG4 RD patients (median 2.46 g/l (range 1.2–23.7)) and dropped to 1.25 g/l (range 0.37–10.4) after therapy; immunoglobulin subclasses were not checked routinely in GPA. All 12 patients with IgG4-RD underwent diagnostic orbital biopsy vs 3/14 GPA (p=0.0001). All 30 patients were treated with corticosteroids (used alone in 3/12 IgG4-RD patients). The median number of DMARDs ever used to treat GPA was 3 vs 1 DMARD for IgG4-RD (p=0.001). Rituximab was effectively administered to 10/14 GPA patients vs 3/12 IgG4-RD (p=0.04), is planned for 2 further IgG4-RD patients and approval was refused for 1 case. Surgical debulking was undertaken in 6/12 IgG4-RD vs 1/14 GPA (p=0.03). All 40 patients had subsequent MRI to assess response to therapy. <h3>Conclusions</h3> IgG4-RD is an important differential diagnosis of infra-orbital inflammation, especially if ANCA is negative. Unlike GPA that was associated with extra-ocular manifestations in all patients, IgG4-RD was more likely to present with isolated orbital inflammation and to require biopsy or surgical debulking as the diagnosis was initially uncertain. Treatment with corticosteroids +/− DMARDs was effective. Rituximab can specifically deplete the pool of autoreactive B lymphocytes producing IgG4 and future systematic studies are required to establish the optimum therapeutic strategy. <h3>Disclosure of Interest</h3> None declared
2-Methoxyestradiol in Combination with Velcade® Results in an Augmentation of NFκB Inhibition, In Vitro Antiproliferative Activity and In Vivo Antitumor Efficacy in the RPMI-8226 Myeloma Model.
Authors: Patricia Burke, Glenn M. Swartz, Cassandra L. Waters, Xiaoru Chen, Theresa M. LaVallee, Anthony M. Treston, William E. Fogler, Carolyn F. Sidor
Journal: Blood (2006)
Role of Rituximab and Intensification with Autologous Stem Cell Transplantation in Primary Mediastinal B-Cell Lymphoma
Authors: Vittorio Ruggero Zilioli, Chiara Rusconi, Cristina Gabutti, Giovanni Grillo, Elisa Zucchetti, Erika Meli, Alessandro Monti, Antonino Greco, Marianna Caramella, Maddalena Mazzucchelli, Michele Nichelatti, Enrica Morra
Journal: Blood (2012)
Defining asthma–COPD overlap syndrome: a population-based study
Authors: Tobias N. Bonten, Marise J. Kasteleyn, Renee de Mutsert, Pieter S. Hiemstra, Frits R. Rosendaal, Niels H. Chavannes, Annelies M. Slats, Christian Taube
Journal: European Respiratory Journal (2017)

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) seems an important clinical phenotype, but multiple definitions have been proposed. This study's objectives were to assess the effect of different ACOS definitions on prevalence, patient characteristics and exacerbations. 5675 individuals aged 45–65 years, with 846 asthma/COPD patients, were included in the Netherlands Epidemiology of Obesity study between 2008 and 2012, and followed-up for a median of 1.8 years. ACOS was defined by recent consensus criteria and five other definitions, based on registry, questionnaires and lung function. Prevalence of ACOS in the asthma/COPD population ranged between 4.4% and 38.3%, depending on the definition used. Agreement between registry-based and self-reported ACOS was 0.04 and 0.41 when lung function (forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) &lt;0.7) was added. With registry or self-report defined ACOS, only 51% and 33% had FEV 1 /FVC &lt;0.7. Patient characteristics were similar, but asthma duration was longer with self-reported compared with registry-based ACOS (mean difference 22 years (95% CI 12–33)). Exacerbation risk was highest with registry-based ACOS compared with asthma (adjusted incidence rate ratio 1.6 (95% CI 1.2–2.1)). This study adds important knowledge about agreement between ACOS definitions and their relation with exacerbations. Given the low agreement, differences in prevalence, patient characteristics and risk of exacerbations, consensus about ACOS definition in different care settings is urgently needed.
Hydroxyurea in the Early Management of Acute Myeloid Leukemia and Hyperleukocytosis.
Authors: Asmaa M. Quessar, Nisrine R. Khoubila, Raul C.U. Ribeiro, Mohamed A. Rachid, Saadia D. Zafad, Mhamed M. Harif, Abdellah L. Madani, Nazha Z. Hda, Scott Howard, Said I. Benchekroun
Journal: Blood (2007)
Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.
Authors: Ruben A. Mesa, Francisco Cervantes, Srdan Verstovsek, Constantine Tam, Brigitte Dupriez, John Reilly, Giovanni Barosi, Megan Campbell, Wenting Wu, A. Pardanani, T. Lasho, Ayalew Tefferi
Journal: Blood (2007)
An Anti-VEGF Antibody, in Combination with Bortezomib, Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma.
Authors: Richard A. Campbell, Eric Sanchez, Jeffrey Steinberg, Michael Share, Joseph Wang, Mingjie Li, Richard Leuchter, Haiming Chen, Dror Shalitin, Shen Pang, Jonathan Said, Gregory D. Plowman, James R. Berenson
Journal: Blood (2007)